Agenda

ORAL PRESENTATIONS OF ORIGINAL RESEARCH WORK AND OF CLINICAL CASES

A Dwarf Overshadowing a Giant. A Case Report.

Caitlyn Kanters, McGill University.

A Special Case of Antiphospholipid Syndrome. A Case Report

Michèle Stanciu, McGill University.

Occult Pan-Aortitis in a Patient with Reactive Arthritis. A Case Report.

Matthew Anacleto-Dubarno, McGill University.

Refractory Gout: A Potential Sign of a Life-Threatening Disease.

Aurélie Mourot, Université de Montréal.

Improving Gout Care in a Canadian Academic Medical Centre Through a Multidisciplinary Nurse-led Program.

Thomas Audet, Service de rhumatologie, Faculté de Médecine et des Sciences de la Santé de l’Université de Sherbrooke.

Conduction Disorders/Dysrhythmias and Hydroxychloroquine in Rheumatoid Arthritis.

Olga Tsyruk, McGill University.

At the end of this session, participants will be better able to:

• Recognize a variety of complex rheumatological entities and manage them.
• Identify, understand and discuss the nature and results of recent research work done by their peers.

“What have canadians learned about conquering new-onset RA?”

Vivian Bykerk, MD, FRCPC

At the end of this session, participants will be better able to provide answers to the following questions:

• Discuss the progress made in RA treatment by earlier interventions.
• Apply the findings of Canadian studies to treatment of patients with early RA.
• Optimize early identification and management of patients with early RA.

ORAL PRESENTATIONS OF ORIGINAL RESEARCH WORK

Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors Does Not Increase Diarrhea-Associated Healthcare Events: Real-world Evidence to Guide Best Practices.

Leah Flatman, McGill University.

Variants génétiques associés aux fractures atypiques des fémurs, une revue narrative de la littérature.

Laurie Champagne, Centre de recherche du CHU de Québec.

At the end of this session, participants will be better able to:

• Identify and understand the nature and results of recent research work done by their peers.

“B Cell Directed CAR T Cells: a Promising Tool for Systemic Autoimmune Diseases?”

Michael Sebag, MD, PhD, FRCPC

At the end of this session, participants will be better able to provide answers to the following questions:

• Understand the principles of B cell directed CAR T cell therapy.
• Discuss their use and benefits in managing hematologic malignancies.
• Discuss their potential benefit and use in systemic autoimmune disease.

“The 2023 ACR/EULAR APS Classification Criteria from a Rheumatologist’s Perspective”

Dr Antonio Cabral, MD

At the end of this session, participants will be better able to:

• Underline novel aspects of the 2023 ACR\EULAR antiphospholipid syndrome classification criteria.
• Discuss that this classification finally acknowledges that APS may have multiple clinical expressions.
• Use the case of thrombocytopenia to illustrate how the new set of criteria is based on self-evident biased experts’ diagnoses to classify what APS is and what it is not.

Dinner & Awards

Jeffrey-Shiroky Award: Dr Suzanne Morin

Roger-Demers Award: Dr Vivian Bykerk

Marie-Thérèse Fortin Award: Dr Nathalie Langlais